SL Science Holding Limited is a biomedical company developing innovative cellular and gene therapies focused on regenerative medicine and cancer treatment. The company's core pipeline includes Armed-T cell therapy (which equips T cells with antibody molecules without genetic modification), proprietary Gamma Delta T cell technology (an off-the-shelf allogeneic cell therapy with broader anti-tumor activity), and exosome-based cosmetic products for skincare. SL Science operates a partnership-driven business model, seeking to license its proprietary cell expansion and engineering platforms to biopharmaceutical companies and earn revenue through milestone payments and royalties on future product sales; while its cell therapy candidates remain in pre-clinical and early development stages, the company markets exosome-derived skincare and hair care products in the cosmetics market as a near-term revenue source.
Financial summary not available yet.